# Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study

> **NCT02805790** · PHASE2 · COMPLETED · sponsor: **Stealth BioTherapeutics Inc.** · enrollment: 30 (actual)

## Conditions studied

- Primary Mitochondrial Disease

## Interventions

- **DRUG:** Elamipretide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02805790
- **Lead sponsor:** Stealth BioTherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-22
- **Primary completion:** 2017-03-10
- **Final completion:** 2017-03-23
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02805790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02805790, "Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02805790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*